15 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
6:07am
treatment that prevented HAE attacks over an extended planned 132 week treatment period across specific HAE patient demographic and disease characteristic
6-K
TAK
Takeda Pharmaceutical Co
10 Feb 22
Current report (foreign)
6:03am
an extended planned 132 week treatment period across specific HAE patient demographic and disease characteristic subgroups. These data were presented
6-K
TAK
Takeda Pharmaceutical Co
5 Nov 21
Current report (foreign)
6:02am
over an extended planned 132 week treatment period across specific HAE patient demographic and disease characteristic subgroups. These data were
6-K
qmniwjxe2iyomzpw
6 Aug 21
Current report (foreign)
6:06am
424B3
3uk6rfdqsoos24wwp
14 Nov 19
Prospectus supplement
6:10am
F-4/A
ng5dg0rplwaail6pj4n
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
5fe6voek6ra
9 Aug 19
Registration of securities (foreign)
6:27am
20-F
x1h4qs3vt8e khjah
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
0el0rgg
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
n7htbx7942ackll0lu
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
uwlpt
16 Nov 18
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next